Latest "Galectin Therapeutics" News Stories

06:57 EDT 25th April 2015 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 59

Relevant

Galectin-3 and Plasma Cytokines in Patients With Acute MI

Could the protein galectin-3 be useful as a circulating biomarker of inflammation associated with acute myocardial infarction? Laboratory Medicine

Bristol-Myers signs exclusive option deal to buy Galecto and new Galectin-3 inhibitor

Bristol-Myers Squibb (BMS) has signed an exclusive option agreement to acquire Denmark-based Galecto Biotech and secure worldwide rights to a new inhaled inhibitor of galectin-3, TD139.

Bristol-Myers Squibb to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

Bristol-Myers Squibb Company and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of g...

Bristol-Myers Squibb to acquire Galecto Biotech AB and its novel Galectin-3 Inhibitor in development for Idiopathic Pulmonary Fibrosis

Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and ga...

Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH patients with advanced fibrosis Both studies to begin in the second quarter of 2015 Company to submit a Special Protocol Assessment to the FDA by the end of the month NORCROSS, Ga., Feb. 24...

Galectin Therapeutics to Present at the 27th Annual ROTH Conference

NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is bei...

BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorporates data generated from a study in which levels of the pr...

Galectin Therapeutics, Inc. - Product Pipeline Review - 2014

Recently added to the BioPortfolio report store, Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 is a new report from Global Markets Direct published on 2014-12-14. This 40-page report is available in PDF from $1500. Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Galectin Therapeutics, Inc. - Product Pipeline Review - 2014’, prov...

Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference

NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST...

The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.

Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update

NORCROSS, Ga., March 18, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ended December 31, 2014. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commiss...

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential

Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Peter G. Traber, M.D., president, chief executive officer and chief medical officer, delivered an invited presentation of the Company's research with lead compound GR-MD-02 in non-alcoholic steatohep...

Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program

NORCROSS, Ga., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Secu...

Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA

NORCROSS, Ga., March 12, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research organization Pharmaceutical Product Development, LLC (PPD) to conduct the Phase 2 trial with GR-MD-02 for the treatment of liver fibrosis and resultant portal hyperten...

The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal–fetal interface in early pregnancy

BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart Association 2014 Scientific Sessions Conference

WALTHAM, Mass., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that 17 abstracts reporting independent research that investigates galectin-3 testing in various cardiovascular diseases have been presented at the American Heart Association's 2014 Scientific Sessions and Resuscitation Science Symposium, which was held in...

Bristol-Myers secures option to buy Danish firm behind inhaled IPF drug

Bristol-Myers Squibb has secured an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead asset TD139, a pipeline drug for idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.Idiopathic pulmonary fibrosis...

Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development

NORCROSS, Ga., Nov. 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Ch...

Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis

NORCROSS, Ga., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that final results from its Phase 1 trial show that GR-MD-02 had an effect on a serum biomarker (as assessed by FibroTest®) and liver stiffness (as assessed by FibroScan®) that suggest a potential for the...

Image of the Day: Snail Blood

The galectin proteins (green) expressed in snail hemocytes—which are equivalent to human white blood cells—bind to the parasitic worm that causes schistosomiasis in people.

BMS Enters Exclusive Agreement to Acquire Galecto's IPF Treatment

Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.

BMS signs exclusive option deal to buy Danish Galecto Biotech

Bristol-Myers Squibb (BMS) has entered into an exclusive option agreement to acquire Denmark-based Galecto Biotech and receive worldwide rights to its inhaled inhibitor of galectin-3, TD139.

La Jolla begins Phase IIb trial of GCS-100 to treat advanced CKD

US-based biotechnology firm La Jolla Pharmaceutical has started a Phase IIb clinical trial of its galectin-3 inhibitor, GCS-100, to treat advanced chronic kidney disease (CKD) caused by diabetes.

Probably Relevant

Bristol Expands Fibrosis Pipeline With Galecto Buy Option

Three-year-old Galecto Biotech on November 3 secured funding and validation from Bristol-Myers Squibb Co. in an option-to-buy deal that could be worth up to $444 million. Galecto’s lead asset, an inhaled inhibitor of galectin-3 in development for i...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks